Ventricular assist devices: Is destination therapy a viable alternative in the non-transplant candidate?

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 101-107

  Hrobowski, Tara ^a   Lanfear, David E ^a,b  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Endstage heart failure; Left ventricular assist device; Mechanical circulatory support; Rotary pumps

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; ASSISTED CIRCULATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DETERIORATION; DEVICE INFECTION; FUNCTIONAL STATUS; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HISTORY OF MEDICINE; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PSYCHOLOGICAL WELL BEING; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SEXUAL FUNCTION; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR ASSIST DEVICE;

EID: 84873720777     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0123-7     Document Type: Article

References (44)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the american heart association. Circulation. 2012;125:e2-e220.
2. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant. 2011;30:1078-94.
3. Institute of Medicine (U.S.), Committee to Evaluate the Artificial Heart Program of the National Heart Lung and Blood Institute, Hogness JR, VanAntwerp M, National Heart Lung and Blood Institute. The artificial heart: prototypes, policies, and patients. Washington, D.C: National Academy Press; 1991.
4. Levitt JA. Thermo Cardiosystems, Inc.; Premarket approval of the HeartMateRegister IP LVAS. In: Services HaH, ed.: Federal Register, 1996:51712, 51713.
5. Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation. 1995;92:II169-73.
6. Sun BC, Catanese KA, Spanier TB, et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg. 1999;68:688-94.
7. Di Bella I, Pagani F, Banfi C, et al. Results with the Novacor assist system and evaluation of long-term assistance. Eur J Cardiothorac Surg. 2000;18:112-6.
8. Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg. 1999;67:723-30.
9. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
10. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007;50:741-7.
11. Jessup M. Mechanical cardiac-support devices-dreams and devilish details. N Engl J Med. 2001;345:1490-3.
12. Dowling RD, Park SJ, Pagani FD, et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur J Cardiothorac Surg. 2004;25:958-63.
13. Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail. 2005;11:133-8.
14. El-Banayosy A, Arusoglu L, Kizner L, et al. Novacor left ventricular assist system versus Heartmate vented electric left ventricular assist system as a long-term mechanical circulatory support device in bridging patients: a prospective study. J Thorac Cardiovasc Surg. 2000;119:581-7.
15. Thomas CE, Jichici D, Petrucci R, Urrutia VC, Schwartzman RJ. Neurologic complications of the Novacor left ventricular assist device. Ann Thorac Surg. 2001;72:1311-5.
16. Saito S, Matsumiya G, Ichikawa H, Matsue H, Sekiya N, Sawa Y. Abdominal fascial enlargement to relieve obstruction of the duodenum caused by Novacor left ventricular assist system. J Heart Lung Transplant. 2007;26:759-62.
17. Samson D. Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Technol Eval Cent Asses Program Exec Summ 2004;19:1.
18. Clegg AJ, Scott DA, Loveman E, et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Health Technol Assess. 2005;9:1-132. iii-iv.
19. •• Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-51. Landmark trial demonstrating clearly superior survival and durability of a continous flow LVAD (Heartmate II) compared to the previous destination LVAD.
20. Salzberg S, Lachat M, Zund G, et al. Left ventricular assist device as bridge to heart transplantation-lessons learned with the MicroMed DeBakey axial blood flow pump. Eur J Cardiothorac Surg. 2003;24:113-8.
21. Westaby S, Siegenthaler M, Beyersdorf F, et al. Destination therapy with a rotary blood pump and novel power delivery. Eur J Cardiothorac Surg. 2010;37:350-6.
22. Esmore D, Kaye D, Spratt P, et al. A prospective, multicenter trial of the VentrAssist left ventricular assist device for bridge to transplant: safety and efficacy. J Heart Lung Transplant. 2008;27:579-88.
23. Strueber M, O'Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol. 2011;57:1375-82.
24. • Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191-200. This multi-center, prospective trial established the HeartWare HVAD in bridge to transplant patients and demonstrated excellent outcomes with over 90 % of patients being alive on device support or transplanted by 6 months.
25. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-96.
26. Fang JC. Rise of the machines-left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med. 2009;361:2282-5.
27. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312-21.
28. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011;57:1890-8.
29. Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241-8.
30. Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant. 2012;31:117-26.
31. Russell SD, Boyle A, Sun B, et al. Risk of bleeding and stroke in 700 HeartMate II LVAD Outpatients. J Heart Lung Transplant 2011;30(4):Supplement, S66.
32. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res. 2010;3:618-24.
33. Swetz KM, Freeman MR, Mueller PS, Park SJ. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:1081.
34. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28:881-7.
35. John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;136:1318-23.
36. Grady KL, Meyer PM, Dressler D, et al. Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation. Ann Thorac Surg. 2004;77:1321-7.
37. • Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55:1826-34. This was an important work in that it is the largest and most thorough examination of the impact of continuous flow LVADs on quality of life and functional capacity. It demonstrated marked and durable improvements in essentially every measure.
38. Marcuccilli L, Casida JJ, Peters RM, Wright S. Sex and intimacy among patients with implantable left-ventricular assist devices. J Cardiovasc Nurs. 2011;26:504-11.
39. Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. Ann Thorac Surg. 2001;71:S195-8. discussion S203-4.
40. Slaughter MS, Bostic R, Tong K, Russo M, Rogers JG. Temporal changes in hospital costs for left ventricular assist device implantation. J Card Surg. 2011;26:535-41.
41. • Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail. 2012;5:10-6. This paper is important as it showed the drastically improving cost-effectiveness of LVADs as destination therapy.
42. Gremeaux V, Troisgros O, Benaim S, et al. Determining the minimal clinically important difference for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome. Arch Phys Med Rehabil. 2011;92:611-9.
43. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail. 2005;11:253-9.
44. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707-15.